Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).

doi:10.1200/JCO.20.01994

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Feb 2021

Kopetz Scott, Guthrie Katherine A, Morris Van K, Lenz Heinz-Josef, Magliocco Anthony M, Maru Dipen, Yan Yibing, Lanman Richard, Manyam Ganiraju, Hong David S, Sorokin Alexey, Atreya Chloe E, Diaz Luis A, Allegra Carmen, Raghav Kanwal P, Wang Stephen E, Lieu Christopher H, McDonough Shannon L, Philip Philip A, Hochster Howard S

Abstract excerpt

PURPOSE: BRAFV600E mutations are rarely associated with objective responses to the BRAF inhibitor vemurafenib in patients with metastatic colorectal cancer (CRC). Blockade of BRAFV600E by vemurafenib causes feedback upregulation of EGFR, whose signaling activities can be impeded by cetuximab. METHODS: One hundred six patients with BRAFV600E-mutated metastatic CRC previously treated with one or two regimens were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Colorectal Neoplasms

Share to Follow-Up Studies

Share to Irinotecan

Share to Neoplasm Metastasis

Share to Proto-Oncogene Proteins B-raf

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 33356422
DOI: 10.1200/JCO.20.01994
PMCID: PMC8462593

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).PMID 33356422Read ↗

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.Semantic proximity Read ↗

A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study.Semantic proximity Read ↗

Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.Semantic proximity Read ↗

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.Semantic proximity Read ↗

The Evolving Treatment Landscape in BRAF-V600E-Mutated Metastatic Colorectal Cancer.Semantic proximity Read ↗

Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.Semantic proximity Read ↗

Vemurafenib, cetuximab and camrelizumab in BRAF V600E-mutated/MSS metastatic colorectal cancer.Semantic proximity Read ↗

Pilot Trial of Combined BRAF and EGFR Inhibition in <i>BRAF</i> -Mutant Metastatic Colorectal Cancer PatientsSemantic proximity Read ↗

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <i>BRAF</i> -Mutant Colorectal Cancers to RAF Inhibition with VemurafenibSemantic proximity Read ↗

Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.Semantic proximity Read ↗

Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.Semantic proximity Read ↗

Vemurafenib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.